Pirfenidone for chronic progressive multiple sclerosis

Multiple Sclerosis

Volumn 7, Issue 5, 2001, Pages 305-312

  Walker, J E ^a   Margolin, S B ^a  

^a Board Certified Psychiatry/Neurology   (United States)

Author keywords

Clinical trials; Disability reduction; Disease stabilization; Pirfenidone (oral); Secondary progressive multiple sclerosis; Tumor necrosis factor alpha

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; INTERFERON BETA SERINE; METHOTREXATE; PIRFENIDONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG WITHDRAWAL; EVALUATION AND FOLLOW UP; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHYSICAL DISABILITY; PILOT STUDY; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR SKILLS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PATIENT DROPOUTS; PILOT PROJECTS; PYRIDONES; RECURRENCE; WALKING;

EID: 0034747862     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245801681138004     Document Type: Article

References (31)

1. Clinical and laboratory features of primary progressive and secondary progressive MS
2. Cytokines in inflammatory brain lesions; Helpful and harmful
3. Increased production of tumor necrosis factor alpha, and not interferon-gamma, preceding disease activity in patients with multiple sclerosis
4. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis
5. Interferon beta-1b treatment modulates TNF-alpha and IFN-gamma spontaneous gene expression in MS
6. Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis
7. Tumor necrosis factor-α production as a possible predictor of relapse in patients with multiple sclerosis
8. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions
9. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system
10. Transgenic models of TNF induced demyelination
11. Remyelination in multiple sclerosis
12. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone
13. Pirfenidone inhibits tumor necrosis factor-alpha and subsequent endotoxin shock
14. Pharmacokinetics of a novel antifibrotic drug, pirfenidone in mouse following intravenous administration
15. Oral pirfenidone in severe chronic progressive multiple sclerosis
16. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
17. A neurologic rating scale (NRS) for use in multiple sclerosis
18. Rating neurologic disability in multiple necrosis: An expanded disability status scale (EDSS)
19. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH
20. Upper extremity function in multiple sclerosis; Improving assessment sensitivity; Box and block and nine-hole peg tests
21. An introductory text
22. Statistical methods
23. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial
24. Pentoxyfylline is not a promising treatment for multiple sclerosis in progression phase
25. Placebo-controlled multi-center randomized trial of interferon-beta-1b in treatment of secondary progressive multiple sclerosis
26. Clinical outcome measures and rating scales in multiple sclerosis trials
27. TNF, apoptosis and autoimmunity: A common thread?
28. Tumor necrosis factor locus: Genetic organization and biological implications
29. Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies
30. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis; A meta-analysis
31. TNF neutralization in MS; Results of a randomized, placebo-controlled multi-center study